Correlation of triglyceride (TG)-to-high density lipoprotein cholesterol (HDL-C) ratio (TG/HDL-C) and the survival of gastric cancer (GC) remain unclear. The purpose of this study was to explore the precise effect of preoperative TG/HDL-C on clinical outcomes in GC patients. Patients with GC were enrolled from 2006 to 2014. A total of 957 individuals from a single center were divided into prospective training and retrospective test cohorts. The optimal cutoff value of TG/HDL-C was determined using X-tile software to separate the training cohort into low and high survival groups according to TG/HDL-C levels. Survival analyses were performed using Kaplan-Meier curves and a Cox proportional hazards regression model. Preoperative TG/HDL-C and clinical outcomes were obtained to determine the prognostic significance of serum lipids in the training and test cohorts. We observed that high TG and TG/HDL-C were significantly correlated with poor outcome in GC patients, and high TG/HDL-C harbored the highest area under curve to independently predict 5-year overall survival in two cohorts. Furthermore, c-index of the prognostic nomogram including TG/HDL-C was significantly higher than that without it. In summary, TG/HDL-C was an efficient and independent prognostic factor to predict 5-year case fatality of GC patients and to improve the efficacy of its prognostic nomogram.

Background: Long noncoding RNA (lncRNA) Z38 has been shown to promote cell proliferation and tumorigenesis in breast cancer. However, expression pattern and prognostic value of lncRNA Z38 in breast cancer patients remain elusive.Methods: The expression levels of SPRY4‐IT1 in 110 self‐paired specimens of breast cancer and adjacent normal breast tissues were measured by quantitative real‐time PCR (qRT‐PCR), and its correlation with overall survival of patients with breast cancer was further statistically analyzed.Results: Compared with normal breast tissues, Z38 was upregulated in breast cancer tissues. Furthermore, of 110 breast cancer patients, high Z38 expression was significantly associated with tumor‐node‐metastasis stage and lymph node metastasis. Further analysis using the Cox regression model revealed that Z38 expression was an independent prognostic factor of overall survival in patients with breast cancer (hazard ratio=4.74, 95% confidence interval 2.41‐9.32). The nomogram presents a good prediction of the probability of overall survival of breast cancer patients (c‐index: 0.792), and its predictive efficiency was further confirmed by the calibration curve.Conclusion: Our data highlighted the potential of lncRNA Z38 as novel candidate biomarker to identify patients with breast cancer at high risk of tumor death.

Objective: E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data. Method: PubMed, Web of Science and CNKI database were searched until May 31^th, 2022 by using key words to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio and 95% confidence interval was calculated with Stata17.0 software. Result: A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I² = 95.3%, *P_{Heterogeneity} = 0.000) and disease-free survival (HR = 1.41, I² = 95.2%, *P_{Heterogeneity} = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper. Conclusion: E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter overall survival and disease-free survival.